Trial
NCT03297463
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Metastatic Melanoma
Intervention
Interleukin-2 & Ipilimumab (P-Ib)
Why stopped
Replaced by another study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-01